UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. __)

Filed by the Registrant \boxtimes

Filed	by a party othe	r than the Registrant □
Checl	k the appropria	e box:
	Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under §240.14a-12	
		LIXTE BIOTECHNOLOGY HOLDINGS, INC.
		(Name of Registrant as Specified in Its Charter)
		(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Paym	ent of Filing Fo	ee (Check the appropriate box):
\boxtimes	No fee requ	ired.
	Fee comput	ted on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. Title of each class of securities to which transaction applies:
	(2)	Aggregate number of securities to which transaction applies:
	(3)	Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
	(4)	Proposed maximum aggregate value of transaction:
	(5)	Total fee paid:
	Fee paid pr	eviously with preliminary materials.
	Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.	
	(1)	Amount Previously Paid:
	(2)	Form, Schedule or Registration Statement No.:
	(3)	Filing Party:
	(4)	Date Filed:





000004

MR A SAMPLE
DESIGNATION (IF ANY)
ADD 1
ADD 2
ADD 3
ADD 4

ADD 5 ADD 6 C 1234567890

Online



Go to www.envisionreports.com/LIXT or scan the QR code — login details are located in the shaded bar below.

Stockholder Meeting Notice

1234 5678 9012 345

Important Notice Regarding the Availability of Proxy Materials for the Lixte Biotechnology Holdings, Inc. Stockholder Meeting to be Held on November 27, 2023.

Under Securities and Exchange Commission rules, you are receiving this notice that the proxy materials for the annual stockholders' meeting are available on the Internet. Follow the instructions below to view the materials and vote online or request a copy. The items to be voted on and location of the annual meeting are on the reverse side. Your vote is important!

This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The Notice, 2023 Proxy Statement and December 31, 2022 Form 10-K Annual Report are available at:

www.envisionreports.com/LIXT



Easy Online Access — View your proxy materials and vote.

Step 1: Go to www.envisionreports.com/LIXT

Step 2: Click on Cast Your Vote or Request Materials.

Step 3: Follow the instructions on the screen to log in.

Step 4: Make your selections as instructed on each screen for your delivery preferences.

Step 5: Vote your shares.

When you go online, you can also help the environment by consenting to receive electronic delivery of future materials.



Obtaining a Copy of the Proxy Materials – If you want to receive a copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. Please make your request as instructed on the reverse side on or before November 17, 2023 to facilitate timely delivery.

2 N O T





Stockholder Meeting Notice

Lixte Biotechnology Holdings, Inc. Annual Meeting of Stockholders will be held on November 27, 2023 at 10:00 am Pacific Time, virtually via the internet at www.meetnow.global/M6YYXWG. To access the virtual meeting, you must have the information that is printed in the shaded bar located on the reverse side of this form.

Proposals to be voted on at the meeting are listed below along with the Board of Directors' recommendations.

The Board of Directors recommend a vote FOR all the nominees listed and FOR Proposals 2 and 3:

- 1. Election of Directors:
 - 01 Bas van der Baan
 - 02 Dr. Stephen Forman
 - 03 Dr. Yun Yen
 - 04 Regina Brown
 - 05 Dr. René Bernards
- 2. RATIFICATION OF THE APPOINTMENT OF WEINBERG & COMPANY, P.A. AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2023
- 3. APPROVAL OF AMENDMENT TO THE LIXTE BIOTECHNOLOGY HOLDINGS, INC. 2020 STOCK INCENTIVE PLAN

PLEASE NOTE - YOU CANNOT VOTE BY RETURNING THIS NOTICE. To vote your shares you must go online or request a paper copy of the proxy materials to receive a proxy card.



Here's how to order a copy of the proxy materials and select delivery preferences:

Current and future delivery requests can be submitted using the options below.

If you request an email copy, you will receive an email with a link to the current meeting materials.

PLEASE NOTE: You must use the number in the shaded bar on the reverse side when requesting a copy of the proxy materials.

- Internet Go to www.envisionreports.com/LIXT. Click Cast Your Vote or Request Materials.
- Phone Call us free of charge at 1-866-641-4276.
- Email Send an email to investorvote@computershare.com with "Proxy Materials Lixte Biotechnology Holdings, Inc." in the subject
 line. Include your full name and address, plus the number located in the shaded bar on the reverse side, and state that you want a
 paper copy of the meeting materials.

To facilitate timely delivery, all requests for a paper copy of proxy materials must be received by November 17, 2023.